;PMID: 11051374
;source_file_1207.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:47..155] = [t:47..155]
;2)section:[e:159..238] = [t:159..238]
;3)section:[e:242..345] = [t:242..345]
;4)sentence:[e:349..359] = [t:349..359]
;5)sentence:[e:360..495] = [t:360..495]
;6)sentence:[e:496..690] = [t:496..690]
;7)sentence:[e:691..699] = [t:691..699]
;8)sentence:[e:700..872] = [t:700..872]
;9)sentence:[e:873..1020] = [t:873..1020]
;10)sentence:[e:1021..1278] = [t:1021..1278]
;11)sentence:[e:1279..1287] = [t:1279..1287]
;12)sentence:[e:1288..1432] = [t:1288..1432]
;13)sentence:[e:1433..1518] = [t:1433..1518]
;14)sentence:[e:1519..1750] = [t:1519..1750]
;15)sentence:[e:1751..1828] = [t:1751..1828]
;16)sentence:[e:1829..1988] = [t:1829..1988]
;17)sentence:[e:1989..2126] = [t:1989..2126]
;18)sentence:[e:2127..2139] = [t:2127..2139]
;19)sentence:[e:2140..2364] = [t:2140..2364]
;20)sentence:[e:2365..2532] = [t:2365..2532]
;21)sentence:[e:2533..2670] = [t:2533..2670]
;22)sentence:[e:2671..2775] = [t:2671..2775]
;23)section:[e:2779..2824] = [t:2779..2824]

;section 0 Span:0..42
;Am J Gastroenterol  2000 Oct;95(10):2953-7
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..18] Gastroenterol)
        (CD:[20..24] 2000) (.:[25..32] Oct;95-LRB-) (CD:[32..34] 10)
        (-RRB-:[34..35] -RRB-) (CD:[35..40] :2953) (::[40..41] -)
        (CD:[41..42] 7)))

;sentence 1 Span:47..155
;Impact of KRAS and TP53 mutations on survival in patients with left- and 
;right-sided Dukes' C colon cancer.
;[57..61]:gene-rna:"KRAS"
;[66..70]:gene-rna:"TP53"
;[110..115]...[127..154]:malignancy:"left-"..."sided Dukes' C colon cancer"
;[121..154]:malignancy:"right-sided Dukes' C colon cancer"
(SENT
  (NP-HLN
    (NP (NN:[47..53] Impact))
    (PP (IN:[54..56] of)
      (NP
        (NP (NN:[57..61] KRAS)
          (NML-1 (-NONE-:[61..61] *P*)))
        (CC:[62..65] and)
        (NP (NN:[66..70] TP53)
          (NML-1 (NNS:[71..80] mutations)))))
    (PP (IN:[81..83] on)
      (NP (NN:[84..92] survival)))
    (PP-LOC (IN:[93..95] in)
      (NP
        (NP (NNS:[96..104] patients))
        (PP (IN:[105..109] with)
          (NP
            (NP
              (ADJP (JJ:[110..114] left) (HYPH:[114..115] -)
                (ADJP-2 (-NONE-:[115..115] *P*)))
              (NML-3 (-NONE-:[115..115] *P*)))
            (CC:[116..119] and)
            (NP
              (ADJP (JJ:[121..126] right) (HYPH:[126..127] -)
                (ADJP-2 (JJ:[127..132] sided)))
              (NML-3
                (NML
                  (NP (NNP:[133..138] Dukes) (POS:[138..139] '))
                  (NN:[140..141] C))
                (NN:[142..147] colon) (NN:[148..154] cancer)))))))
    (.:[154..155] .)))

;section 2 Span:159..238
;Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, Plukker
;JT.
(SEC
  (FRAG (NNP:[159..166] Bleeker) (NNP:[167..169] WA) (,:[169..170] ,)
        (NNP:[171..176] Hayes) (NNP:[177..179] VM) (,:[179..180] ,)
        (NNP:[181..191] Karrenbeld) (NNP:[192..193] A) (,:[193..194] ,)
        (NNP:[195..202] Hofstra) (NNP:[203..205] RM) (,:[205..206] ,)
        (NNP:[207..214] Hermans) (NNP:[215..217] J,) (NNP:[218..222] Buys)
        (NNP:[223..225] CC) (,:[225..226] ,) (NNP:[227..234] Plukker)
        (NNP:[235..238] JT.)))

;section 3 Span:242..345
;Department of Surgery, Medical Genetics and Pathology, University Hospital 
;Groningen, The Netherlands.
(SEC
  (FRAG (NNP:[242..252] Department) (IN:[253..255] of) (NNP:[256..263] Surgery)
        (,:[263..264] ,) (NNP:[265..272] Medical) (NNP:[273..281] Genetics)
        (CC:[282..285] and) (NNP:[286..295] Pathology) (,:[295..296] ,)
        (NNP:[297..307] University) (NNP:[308..316] Hospital)
        (NNP:[318..327] Groningen) (,:[327..328] ,) (DT:[329..332] The)
        (NNP:[333..344] Netherlands) (.:[344..345] .)))

;sentence 4 Span:349..359
;OBJECTIVE:
(SENT
  (NP (NN:[349..358] OBJECTIVE) (::[358..359] :)))

;sentence 5 Span:360..495
;It has been suggested that KRAS and TP53 mutated tumors might  influence the
;phenotypic behavior of left- and right-sided colon tumors.
;[387..391]:gene-rna:"KRAS"
;[396..400]:gene-rna:"TP53"
;[409..415]:malignancy:"tumors"
;[460..465]...[476..494]:malignancy:"left-"..."sided colon tumors"
;[470..494]:malignancy:"right-sided colon tumors"
(SENT
  (S
    (NP-SBJ-1
      (NP (PRP:[360..362] It))
      (SBAR-2 (-NONE-:[362..362] *EXP*)))
    (VP (VBZ:[363..366] has)
      (VP (VBN:[367..371] been)
        (VP (VBN:[372..381] suggested)
          (NP-1 (-NONE-:[381..381] *))
          (SBAR-2 (IN:[382..386] that)
            (S
              (NP-SBJ
                (NP
                  (ADJP (NN:[387..391] KRAS)
                    (ADJP-3 (-NONE-:[391..391] *P*)))
                  (NML-4 (-NONE-:[391..391] *P*)))
                (CC:[392..395] and)
                (NP
                  (ADJP (NN:[396..400] TP53)
                    (ADJP-3 (VBN:[401..408] mutated)))
                  (NML-4 (NNS:[409..415] tumors))))
              (VP (MD:[416..421] might)
                (VP (VB:[423..432] influence)
                  (NP
                    (NP (DT:[433..436] the) (JJ:[437..447] phenotypic)
                        (NN:[448..456] behavior))
                    (PP (IN:[457..459] of)
                      (NP
                        (NP
                          (ADJP (JJ:[460..464] left) (HYPH:[464..465] -)
                            (ADJP-5 (-NONE-:[465..465] *P*)))
                          (NML-6 (-NONE-:[465..465] *P*)))
                        (CC:[466..469] and)
                        (NP
                          (ADJP (JJ:[470..475] right) (HYPH:[475..476] -)
                            (ADJP-5 (JJ:[476..481] sided)))
                          (NML-6 (NN:[482..487] colon) (NNS:[488..494] tumors)))))))))))))
    (.:[494..495] .)))

;sentence 6 Span:496..690
;We  investigated the incidence of these mutations in left- and right-sided
;colon  tumors and their possible influence on survival in a homogeneous group
;of  patients with Dukes' C colon cancers.
;[549..554]...[565..584]:malignancy:"left-"..."sided colon  tumors"
;[559..584]:malignancy:"right-sided colon  tumors"
;[667..689]:malignancy:"Dukes' C colon cancers"
(SENT
  (S
    (NP-SBJ (PRP:[496..498] We))
    (VP (VBD:[500..512] investigated)
      (NP
        (NP
          (NP (DT:[513..516] the) (NN:[517..526] incidence))
          (PP (IN:[527..529] of)
            (NP
              (NP (DT:[530..535] these) (NNS:[536..545] mutations))
              (PP (IN:[546..548] in)
                (NP
                  (NP
                    (ADJP (JJ:[549..553] left) (HYPH:[553..554] -)
                      (ADJP-1 (-NONE-:[554..554] *P*)))
                    (NML-2 (-NONE-:[554..554] *P*)))
                  (CC:[555..558] and)
                  (NP
                    (ADJP (JJ:[559..564] right) (HYPH:[564..565] -)
                      (ADJP-1 (JJ:[565..570] sided)))
                    (NML-2 (NN:[571..576] colon) (NNS:[578..584] tumors))))))))
        (CC:[585..588] and)
        (NP
          (NP (PRP$:[589..594] their) (JJ:[595..603] possible)
              (NN:[604..613] influence))
          (PP (IN:[614..616] on)
            (NP (NN:[617..625] survival)))))
      (PP-LOC (IN:[626..628] in)
        (NP
          (NP (DT:[629..630] a) (JJ:[631..642] homogeneous)
              (NN:[643..648] group))
          (PP (IN:[649..651] of)
            (NP
              (NP (NNS:[653..661] patients))
              (PP (IN:[662..666] with)
                (NP
                  (NP
                    (NP (NNP:[667..672] Dukes) (POS:[672..673] '))
                    (NN:[674..675] C))
                  (NN:[676..681] colon) (NNS:[682..689] cancers))))))))
    (.:[689..690] .)))

;sentence 7 Span:691..699
;METHODS:
(SENT
  (NP (NNS:[691..698] METHODS) (::[698..699] :)))

;sentence 8 Span:700..872
;The primary tumors of 55 patients  with a sporadic Dukes' C colon cancer, all
;treated with adjuvant chemotherapy  were analyzed for the presence of KRAS
;and TP53 mutations.
;[704..718]:malignancy:"primary tumors"
;[742..772]:malignancy:"sporadic Dukes' C colon cancer"
;[848..852]:gene-rna:"KRAS"
;[857..861]:gene-rna:"TP53"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[700..703] The)
         (JJ:[704..711] primary) (NNS:[712..718] tumors))
      (PP (IN:[719..721] of)
        (NP
          (NP (CD:[722..724] 55) (NNS:[725..733] patients))
          (PP (IN:[735..739] with)
            (NP (DT:[740..741] a)
               (JJ:[742..750] sporadic)
              (NML
                (NP (NNP:[751..756] Dukes) (POS:[756..757] '))
                (NN:[758..759] C))
              (NN:[760..765] colon) (NN:[766..772] cancer)))))
      (,:[772..773] ,)
      (VP (DT:[774..777] all) (VBN:[778..785] treated)
        (NP (-NONE-:[785..785] *))
        (PP-MNR (IN:[786..790] with)
          (NP (JJ:[791..799] adjuvant) (NN:[800..812] chemotherapy)))))
    (VP (VBD:[814..818] were)
      (VP (VBN:[819..827] analyzed)
        (NP-1 (-NONE-:[827..827] *))
        (PP (IN:[828..831] for)
          (NP
            (NP (DT:[832..835] the) (NN:[836..844] presence))
            (PP (IN:[845..847] of)
              (NP
                (NP (NN:[848..852] KRAS)
                  (NML-2 (-NONE-:[852..852] *P*)))
                (CC:[853..856] and)
                (NP (NN:[857..861] TP53)
                  (NML-2 (NNS:[862..871] mutations)))))))))
    (.:[871..872] .)))

;sentence 9 Span:873..1020
;Mutation detection of  the KRAS and TP53 genes was performed on
;paraffin-embedded tumor material, using  denaturating gradient gel
;electrophoresis.
;[900..904]:gene-rna:"KRAS"
;[909..913]:gene-rna:"TP53"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[873..881] Mutation) (NN:[882..891] detection))
      (PP (IN:[892..894] of)
        (NP (DT:[896..899] the)
          (NML
            (NML (NN:[900..904] KRAS)
              (NML-2 (-NONE-:[904..904] *P*)))
            (CC:[905..908] and)
            (NML (NN:[909..913] TP53)
              (NML-2 (NNS:[914..919] genes)))))))
    (VP (VBD:[920..923] was)
      (VP (VBN:[924..933] performed)
        (NP-1 (-NONE-:[933..933] *))
        (PP (IN:[934..936] on)
          (NP
            (ADJP (NN:[937..945] paraffin) (HYPH:[945..946] -)
                  (VBN:[946..954] embedded))
            (NN:[955..960] tumor) (NN:[961..969] material)))
        (,:[969..970] ,)
        (S-MNR
          (NP-SBJ (-NONE-:[970..970] *))
          (VP (VBG:[971..976] using)
            (NP (VBG:[978..990] denaturating) (NN:[991..999] gradient)
                (NN:[1000..1003] gel) (NN:[1004..1019] electrophoresis))))))
    (.:[1019..1020] .)))

;sentence 10 Span:1021..1278
;The 5-yr survival rates of KRAS and  TP53 mutated tumors were analyzed
;regarding right-sided tumors (defined as  tumors up to the splenic flexure)
;and left-sided tumors (defined as tumors from  the splenic flexure to the
;rectosigmoid peritoneal reflection).
;[1048..1052]:gene-rna:"KRAS"
;[1058..1062]:gene-rna:"TP53"
;[1071..1077]:malignancy:"tumors"
;[1102..1120]:malignancy:"right-sided tumors"
;[1134..1166]:malignancy:"tumors up to the splenic flexure"
;[1172..1189]:malignancy:"left-sided tumors"
;[1202..1276]:malignancy:"tumors from  the splenic flexure to the rectosigmoid
;peritoneal reflection"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1021..1024] The)
        (NML (CD:[1025..1026] 5) (HYPH:[1026..1027] -) (NN:[1027..1029] yr))
        (NN:[1030..1038] survival) (NNS:[1039..1044] rates))
      (PP (IN:[1045..1047] of)
        (NP
          (NP
            (ADJP (NN:[1048..1052] KRAS)
              (ADJP-1 (-NONE-:[1052..1052] *P*)))
            (NML-3 (-NONE-:[1052..1052] *P*)))
          (CC:[1053..1056] and)
          (NP
            (ADJP (NN:[1058..1062] TP53)
              (ADJP-1 (VBN:[1063..1070] mutated)))
            (NML-3 (NNS:[1071..1077] tumors))))))
    (VP (VBD:[1078..1082] were)
      (VP (VBN:[1083..1091] analyzed)
        (NP-2 (-NONE-:[1091..1091] *))
        (PP (VBG:[1092..1101] regarding)
          (NP
            (NP
              
              (ADJP (JJ:[1102..1107] right) (HYPH:[1107..1108] -)
                    (JJ:[1108..1113] sided))
              (NNS:[1114..1120] tumors)
              (PRN (-LRB-:[1121..1122] -LRB-)
                (VP (VBN:[1122..1129] defined)
                  (NP (-NONE-:[1129..1129] *))
                  (PP-CLR (IN:[1130..1132] as)
                    (NP
                      (NP (NNS:[1134..1140] tumors))
                      (PP (IN:[1141..1143] up)
                        (PP (TO:[1144..1146] to)
                          (NP (DT:[1147..1150] the) (JJ:[1151..1158] splenic)
                              (NN:[1159..1166] flexure)))))))
                (-RRB-:[1166..1167] -RRB-)))
            (CC:[1168..1171] and)
            (NP
              
              (ADJP (JJ:[1172..1176] left) (HYPH:[1176..1177] -)
                    (JJ:[1177..1182] sided))
              (NNS:[1183..1189] tumors)
              (PRN (-LRB-:[1190..1191] -LRB-)
                (VP (VBN:[1191..1198] defined)
                  (NP (-NONE-:[1198..1198] *))
                  (PP-CLR (IN:[1199..1201] as)
                    (NP
                      (NP (NNS:[1202..1208] tumors))
                      (PP (IN:[1209..1213] from)
                        (NP
                          (NP (DT:[1215..1218] the) (JJ:[1219..1226] splenic)
                              (NN:[1227..1234] flexure))
                          (PP (TO:[1235..1237] to)
                            (NP (DT:[1238..1241] the)
                                (JJ:[1242..1254] rectosigmoid)
                                (JJ:[1255..1265] peritoneal)
                                (NN:[1266..1276] reflection))))))))
                (-RRB-:[1276..1277] -RRB-)))))))
    (.:[1277..1278] .)))

;sentence 11 Span:1279..1287
;RESULTS:
(SENT
  (NP (NNS:[1279..1286] RESULTS) (::[1286..1287] :)))

;sentence 12 Span:1288..1432
;KRAS  mutations occurred more frequently in the right colon compared to the
;left colon  (R = 38% (10/26); L = 10% (3/29); chi2 test: p = 0.014).
;[1288..1292]:gene-rna:"KRAS"
(SENT
  (S
    (NP-SBJ (NN:[1288..1292] KRAS) (NNS:[1294..1303] mutations))
    (VP (VBD:[1304..1312] occurred)
      (ADVP-TMP (RBR:[1313..1317] more) (RB:[1318..1328] frequently))
      (PP-LOC (IN:[1329..1331] in)
        (NP (DT:[1332..1335] the) (JJ:[1336..1341] right)
            (NN:[1342..1347] colon)))
      (S-ADV
        (NP-SBJ (-NONE-:[1347..1347] *))
        (VP (VBN:[1348..1356] compared)
          (PP-CLR (TO:[1357..1359] to)
            (NP (DT:[1360..1363] the) (JJ:[1364..1368] left)
                (NN:[1369..1374] colon)))
          (PRN (-LRB-:[1376..1377] -LRB-)
            (S
              (NP-SBJ (NN:[1377..1378] R))
              (VP (SYM:[1379..1380] =)
                (NP (CD:[1381..1383] 38) (NN:[1383..1384] %)
                  (PRN (-LRB-:[1385..1386] -LRB-)
                    (NP
                      (NP (CD:[1386..1388] 10))
                      (PP (SYM:[1388..1389] /)
                        (NP (CD:[1389..1391] 26))))
                    (-RRB-:[1391..1392] -RRB-)))))
            (::[1392..1393] ;)
            (S
              (NP-SBJ (NN:[1394..1395] L))
              (VP (SYM:[1396..1397] =)
                (NP (CD:[1398..1400] 10) (NN:[1400..1401] %)
                  (PRN (-LRB-:[1402..1403] -LRB-)
                    (NP
                      (NP (CD:[1403..1404] 3))
                      (PP (SYM:[1404..1405] /)
                        (NP (CD:[1405..1407] 29))))
                    (-RRB-:[1407..1408] -RRB-)))))
            (::[1408..1409] ;)
            (FRAG
              (NP (NN:[1410..1414] chi2) (NN:[1415..1419] test))
              (::[1419..1420] :)
              (S
                (NP-SBJ (NN:[1421..1422] p))
                (VP (SYM:[1423..1424] =)
                  (NP (CD:[1425..1430] 0.014)))))
            (-RRB-:[1430..1431] -RRB-)))))
    (.:[1431..1432] .)))

;sentence 13 Span:1433..1518
;KRAS mutations did not  influence survival in patients with right-sided colon
;tumors.
;[1433..1437]:gene-rna:"KRAS"
;[1493..1517]:malignancy:"right-sided colon tumors"
(SENT
  (S
    (NP-SBJ (NN:[1433..1437] KRAS) (NNS:[1438..1447] mutations))
    (VP (VBD:[1448..1451] did) (RB:[1452..1455] not)
      (VP (VB:[1457..1466] influence)
        (NP (NN:[1467..1475] survival))
        (PP-LOC (IN:[1476..1478] in)
          (NP
            (NP (NNS:[1479..1487] patients))
            (PP (IN:[1488..1492] with)
              (NP
                (ADJP (JJ:[1493..1498] right) (HYPH:[1498..1499] -)
                      (JJ:[1499..1504] sided))
                (NN:[1505..1510] colon) (NNS:[1511..1517] tumors)))))))
    (.:[1517..1518] .)))

;sentence 14 Span:1519..1750
;Patients with KRAS  mutation-negative tumors in the right colon, however, had
;a significantly worse  survival than patients with left-sided KRAS
;mutation-negative tumors (5-yr  survival; R: 34% vs L: 65%, log-rank test: p
;= 0.007).
;[1533..1537]:gene-rna:"KRAS"
;[1557..1582]:malignancy:"tumors in the right colon"
;[1659..1663]:gene-rna:"KRAS"
;[1682..1688]:malignancy:"tumors"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1519..1527] Patients))
      (PP (IN:[1528..1532] with)
        (NP
          (NP
            (ADJP
              (NML (NN:[1533..1537] KRAS) (NN:[1539..1547] mutation))
              (HYPH:[1547..1548] -) (JJ:[1548..1556] negative))
            (NNS:[1557..1563] tumors))
          (PP-LOC (IN:[1564..1566] in)
            (NP (DT:[1567..1570] the) (JJ:[1571..1576] right)
                (NN:[1577..1582] colon))))))
    (,:[1582..1583] ,)
    (ADVP (RB:[1584..1591] however))
    (,:[1591..1592] ,)
    (VP (VBD:[1593..1596] had)
      (NP
        (NP (DT:[1597..1598] a)
          (ADJP (RB:[1599..1612] significantly) (JJR:[1613..1618] worse))
          (NN:[1620..1628] survival))
        (PP (IN:[1629..1633] than)
          (NP
            (NP (NNS:[1634..1642] patients))
            (PP (IN:[1643..1647] with)
              (NP
                (ADJP (JJ:[1648..1652] left) (HYPH:[1652..1653] -)
                      (JJ:[1653..1658] sided))
                (ADJP
                  (NML (NN:[1659..1663] KRAS) (NN:[1664..1672] mutation))
                  (HYPH:[1672..1673] -) (JJ:[1673..1681] negative))
                (NNS:[1682..1688] tumors))))))
      (PRN (-LRB-:[1689..1690] -LRB-)
        (FRAG
          (NP
            (NML (CD:[1690..1691] 5) (HYPH:[1691..1692] -) (NN:[1692..1694] yr))
            (NN:[1696..1704] survival))
          (::[1704..1705] ;)
          (S
            (S
              (NP-SBJ (NN:[1706..1707] R))
              (::[1707..1708] :)
              (NP-PRD (CD:[1709..1711] 34)
                (NML (NN:[1711..1712] %))))
            (IN:[1713..1715] vs)
            (S
              (NP-SBJ (NN:[1716..1717] L))
              (::[1717..1718] :)
              (NP-PRD (CD:[1719..1721] 65) (NN:[1721..1722] %)))))
        (,:[1722..1723] ,)
        (FRAG
          (NP
            (NML (NN:[1724..1727] log) (HYPH:[1727..1728] -)
                 (NN:[1728..1732] rank))
            (NN:[1733..1737] test))
          (::[1737..1738] :)
          (S
            (NP-SBJ (NN:[1739..1740] p))
            (VP (SYM:[1741..1742] =)
              (NP (CD:[1743..1748] 0.007)))))
        (-RRB-:[1748..1749] -RRB-)))
    (.:[1749..1750] .)))

;sentence 15 Span:1751..1828
;TP53 mutations of a  possible causative nature were found in 24 tumors
;(44%).
;[1751..1755]:gene-rna:"TP53"
;[1815..1821]:malignancy:"tumors"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1751..1755] TP53) (NNS:[1756..1765] mutations))
      (PP (IN:[1766..1768] of)
        (NP (DT:[1769..1770] a) (JJ:[1772..1780] possible)
            (JJ:[1781..1790] causative) (NN:[1791..1797] nature))))
    (VP (VBD:[1798..1802] were)
      (VP (VBN:[1803..1808] found)
        (NP-1 (-NONE-:[1808..1808] *))
        (PP-LOC (IN:[1809..1811] in)
          (NP (CD:[1812..1814] 24) (NNS:[1815..1821] tumors)
            (PRN (-LRB-:[1822..1823] -LRB-)
              (NP (CD:[1823..1825] 44) (NN:[1825..1826] %))
              (-RRB-:[1826..1827] -RRB-))))))
    (.:[1827..1828] .)))

;sentence 16 Span:1829..1988
;Neither the incidence  (R = 42% (11/26); L = 45% (13/29)) nor the survival of
;TP53 mutated tumors  differed significantly between left- and right-sided
;tumors.
;[1907..1911]:gene-rna:"TP53"
;[1920..1926]:malignancy:"tumors"
;[1959..1964]...[1975..1987]:malignancy:"left-"..."sided tumors"
;[1969..1987]:malignancy:"right-sided tumors"
(SENT
  (S
    (NP-SBJ
      (NP (CC:[1829..1836] Neither)
        (NP (DT:[1837..1840] the) (NN:[1841..1850] incidence)
          (PRN (-LRB-:[1852..1853] -LRB-)
            (S
              (S
                (NP-SBJ (NN:[1853..1854] R))
                (VP (SYM:[1855..1856] =)
                  (NP (CD:[1857..1859] 42) (NN:[1859..1860] %)
                    (PRN (-LRB-:[1861..1862] -LRB-)
                      (NP
                        (NP (CD:[1862..1864] 11))
                        (PP (SYM:[1864..1865] /)
                          (NP (CD:[1865..1867] 26))))
                      (-RRB-:[1867..1868] -RRB-)))))
              (::[1868..1869] ;)
              (S
                (NP-SBJ (NN:[1870..1871] L))
                (VP (SYM:[1872..1873] =)
                  (NP (CD:[1874..1876] 45) (NN:[1876..1877] %)
                    (PRN (-LRB-:[1878..1879] -LRB-)
                      (NP
                        (NP (CD:[1879..1881] 13))
                        (PP (SYM:[1881..1882] /)
                          (NP (CD:[1882..1884] 29))))
                      (-RRB-:[1884..1885] -RRB-))))))
            (-RRB-:[1885..1886] -RRB-)))
        (CC:[1887..1890] nor)
        (NP (DT:[1891..1894] the) (NN:[1895..1903] survival)))
      (PP (IN:[1904..1906] of)
        (NP
          (ADJP (NN:[1907..1911] TP53) (VBN:[1912..1919] mutated))
          (NNS:[1920..1926] tumors))))
    (VP (VBD:[1928..1936] differed)
      (ADVP (RB:[1937..1950] significantly))
      (PP (IN:[1951..1958] between)
        (NP
          (NP
            (ADJP (JJ:[1959..1963] left) (HYPH:[1963..1964] -)
              (ADJP-1 (-NONE-:[1964..1964] *P*)))
            (NML-2 (-NONE-:[1964..1964] *P*)))
          (CC:[1965..1968] and)
          (NP
            (ADJP (JJ:[1969..1974] right) (HYPH:[1974..1975] -)
              (ADJP-1 (JJ:[1975..1980] sided)))
            (NML-2 (NNS:[1981..1987] tumors))))))
    (.:[1987..1988] .)))

;sentence 17 Span:1989..2126
;Furthermore,  survival of patients with TP53 mutation-negative tumors did not
;differ  significantly between left- and right-sided tumors.
;[2029..2033]:gene-rna:"TP53"
;[2052..2058]:malignancy:"tumors"
;[2097..2102]...[2113..2125]:malignancy:"left-"..."sided tumors"
;[2107..2125]:malignancy:"right-sided tumors"
(SENT
  (S
    (ADVP (RB:[1989..2000] Furthermore))
    (,:[2000..2001] ,)
    (NP-SBJ
      (NP (NN:[2003..2011] survival))
      (PP (IN:[2012..2014] of)
        (NP
          (NP (NNS:[2015..2023] patients))
          (PP (IN:[2024..2028] with)
            (NP
              (ADJP
                (NML (NN:[2029..2033] TP53) (NN:[2034..2042] mutation))
                (HYPH:[2042..2043] -) (JJ:[2043..2051] negative))
              (NNS:[2052..2058] tumors))))))
    (VP (VBD:[2059..2062] did) (RB:[2063..2066] not)
      (VP (VB:[2067..2073] differ)
        (ADVP (RB:[2075..2088] significantly))
        (PP (IN:[2089..2096] between)
          (NP
            (NP
              (ADJP (JJ:[2097..2101] left) (HYPH:[2101..2102] -)
                (ADJP-1 (-NONE-:[2102..2102] *P*)))
              (NML-2 (-NONE-:[2102..2102] *P*)))
            (CC:[2103..2106] and)
            (NP
              (ADJP (JJ:[2107..2112] right) (HYPH:[2112..2113] -)
                (ADJP-1 (JJ:[2113..2118] sided)))
              (NML-2 (NNS:[2119..2125] tumors)))))))
    (.:[2125..2126] .)))

;sentence 18 Span:2127..2139
;CONCLUSIONS:
(SENT
  (NP (NNS:[2127..2138] CONCLUSIONS) (::[2138..2139] :)))

;sentence 19 Span:2140..2364
;There seems to  be no difference in survival rate between patients with KRAS
;mutated and KRAS  negative Dukes' C colon tumors; however, KRAS mutations are
;more frequently  found in the right colon compared to the left colon.
;[2212..2216]:gene-rna:"KRAS"
;[2229..2233]:gene-rna:"KRAS"
;[2244..2265]:malignancy:"Dukes' C colon tumors"
;[2276..2280]:gene-rna:"KRAS"
(SENT
  (S
    (S
      (NP-SBJ-1 (EX:[2140..2145] There))
      (VP (VBZ:[2146..2151] seems)
        (S
          (NP-SBJ-1 (-NONE-:[2151..2151] *))
          (VP (TO:[2152..2154] to)
            (VP (VB:[2156..2158] be)
              (NP-PRD
                (NP (DT:[2159..2161] no) (NN:[2162..2172] difference))
                (PP (IN:[2173..2175] in)
                  (NP (NN:[2176..2184] survival) (NN:[2185..2189] rate)))
                (PP (IN:[2190..2197] between)
                  (NP
                    (NP (NNS:[2198..2206] patients))
                    (PP (IN:[2207..2211] with)
                      (NP
                        (NP
                          (ADJP (NN:[2212..2216] KRAS)
                                (VBN:[2217..2224] mutated))
                          (NML-2 (-NONE-:[2224..2224] *P*)))
                        (CC:[2225..2228] and)
                        (NP
                          (ADJP (NN:[2229..2233] KRAS)
                                (JJ:[2235..2243] negative))
                          (NML-2
                            (NML
                              (NP (NNP:[2244..2249] Dukes) (POS:[2249..2250] '))
                              (NN:[2251..2252] C))
                            (NN:[2253..2258] colon) (NNS:[2259..2265] tumors)))))))))))))
    (::[2265..2266] ;)
    (S
      (ADVP (RB:[2267..2274] however))
      (,:[2274..2275] ,)
      (NP-SBJ-3 (NN:[2276..2280] KRAS) (NNS:[2281..2290] mutations))
      (VP (VBP:[2291..2294] are)
        (ADVP (RBR:[2295..2299] more) (RB:[2300..2310] frequently))
        (VP (VBN:[2312..2317] found)
          (NP-3 (-NONE-:[2317..2317] *))
          (PP-LOC (IN:[2318..2320] in)
            (NP
              (NP (DT:[2321..2324] the) (JJ:[2325..2330] right)
                  (NN:[2331..2336] colon))
              (VP (VBN:[2337..2345] compared)
                (NP (-NONE-:[2345..2345] *))
                (PP-CLR (TO:[2346..2348] to)
                  (NP (DT:[2349..2352] the) (JJ:[2353..2357] left)
                      (NN:[2358..2363] colon)))))))))
    (.:[2363..2364] .)))

;sentence 20 Span:2365..2532
;TP53 mutations do not have  predominance for either side of the colon, and
;there are no differences in  survival in patients with left-sided versus
;right-sided tumors.
;[2365..2369]:gene-rna:"TP53"
;[2495..2505]...[2525..2531]:malignancy:"left-sided"..."tumors"
;[2513..2531]:malignancy:"right-sided tumors"
(SENT
  (S
    (S
      (NP-SBJ (NN:[2365..2369] TP53) (NNS:[2370..2379] mutations))
      (VP (VBP:[2380..2382] do) (RB:[2383..2386] not)
        (VP (VB:[2387..2391] have)
          (NP
            (NP (NN:[2393..2405] predominance))
            (PP (IN:[2406..2409] for)
              (NP
                (NP (DT:[2410..2416] either) (NN:[2417..2421] side))
                (PP (IN:[2422..2424] of)
                  (NP (DT:[2425..2428] the) (NN:[2429..2434] colon)))))))))
    (,:[2434..2435] ,) (CC:[2436..2439] and)
    (S
      (NP-SBJ (EX:[2440..2445] there))
      (VP (VBP:[2446..2449] are)
        (NP-PRD
          (NP (DT:[2450..2452] no) (NNS:[2453..2464] differences))
          (PP (IN:[2465..2467] in)
            (NP (NN:[2469..2477] survival))))
        (PP (IN:[2478..2480] in)
          (NP
            (NP (NNS:[2481..2489] patients))
            (PP (IN:[2490..2494] with)
              (NP
                (NP
                  (ADJP (JJ:[2495..2499] left) (HYPH:[2499..2500] -)
                        (JJ:[2500..2505] sided))
                  (NML-1 (-NONE-:[2505..2505] *P*)))
                (IN:[2506..2512] versus)
                (NP
                  (ADJP (JJ:[2513..2518] right) (HYPH:[2518..2519] -)
                        (JJ:[2519..2524] sided))
                  (NML-1 (NNS:[2525..2531] tumors)))))))))
    (.:[2531..2532] .)))

;sentence 21 Span:2533..2670
;Patients with  KRAS-nonmutated tumors in the right colon did have a worse
;survival compared to  those with such tumors in the left colon.
;[2548..2552]:gene-rna:"KRAS"
;[2564..2589]:malignancy:"tumors in the right colon"
;[2645..2669]:malignancy:"tumors in the left colon"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[2533..2541] Patients))
      (PP (IN:[2542..2546] with)
        (NP
          (NP
            (ADJP (NN:[2548..2552] KRAS) (HYPH:[2552..2553] -)
                  (JJ:[2553..2563] nonmutated))
            (NNS:[2564..2570] tumors))
          (PP-LOC (IN:[2571..2573] in)
            (NP (DT:[2574..2577] the) (JJ:[2578..2583] right)
                (NN:[2584..2589] colon))))))
    (VP (VBD:[2590..2593] did)
      (VP (VB:[2594..2598] have)
        (NP (DT:[2599..2600] a) (JJR:[2601..2606] worse)
            (NN:[2607..2615] survival))
        (S-ADV
          (NP-SBJ-1 (-NONE-:[2615..2615] *))
          (VP (VBN:[2616..2624] compared)
            (NP-1 (-NONE-:[2624..2624] *))
            (PP-CLR (TO:[2625..2627] to)
              (NP
                (NP (DT:[2629..2634] those))
                (PP (IN:[2635..2639] with)
                  (NP
                    (NP (JJ:[2640..2644] such) (NNS:[2645..2651] tumors))
                    (PP-LOC (IN:[2652..2654] in)
                      (NP (DT:[2655..2658] the) (JJ:[2659..2663] left)
                          (NN:[2664..2669] colon)))))))))))
    (.:[2669..2670] .)))

;sentence 22 Span:2671..2775
;This suggests that other genetic  factors may play a role in tumor genesis in
;this subgroup of patients.
(SENT
  (S
    (NP-SBJ (DT:[2671..2675] This))
    (VP (VBZ:[2676..2684] suggests)
      (SBAR (IN:[2685..2689] that)
        (S
          (NP-SBJ (JJ:[2690..2695] other) (JJ:[2696..2703] genetic)
                  (NNS:[2705..2712] factors))
          (VP (MD:[2713..2716] may)
            (VP (VB:[2717..2721] play)
              (NP (DT:[2722..2723] a) (NN:[2724..2728] role))
              (PP (IN:[2729..2731] in)
                (NP (NN:[2732..2737] tumor) (NN:[2738..2745] genesis)))
              (PP (IN:[2746..2748] in)
                (NP
                  (NP (DT:[2749..2753] this) (NN:[2754..2762] subgroup))
                  (PP (IN:[2763..2765] of)
                    (NP (NNS:[2766..2774] patients))))))))))
    (.:[2774..2775] .)))

;section 23 Span:2779..2824
;PMID: 11051374 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2779..2783] PMID) (::[2783..2784] :) (CD:[2785..2793] 11051374)
        (-LRB-:[2794..2795] -LSB-) (NNP:[2795..2801] PubMed) (::[2802..2803] -)
        (VBN:[2804..2811] indexed) (IN:[2812..2815] for)
        (NNP:[2816..2823] MEDLINE) (-RRB-:[2823..2824] -RSB-)))